Strategic fit Target Astellas Engineered Small Molecules U.K. Ltd. as a potential partner for small molecule therapeutic development and collaboration, leveraging their focus within biotechnology research and affiliation with Astellas to access broader translational capabilities.

Global expansion Align with their parent company’s aggressive U.S. and Europe expansion footprint (new facilities and research centers in Massachusetts, Cambridge, San Francisco, Sanford, Westborough, Mexico City, Ireland) to propose co-investment opportunities, joint manufacturing pilots, or regional access programs.

Tech-enabled selling Leverage their listed tech stack (Qlik, MongoDB, Oracle ERP, Intune, Asana, MuleSoft, Smartsheet, Piwik PRO Core) to position compatible data integration, project management, and analytics partnerships that streamline collaborative R&D workflows.

Lower revenue focus With current revenue under one million and modest funding, pursue early-stage, cost-effective collaboration models such as feasibility studies, royalty-backed partnerships, or grant-aligned research programs to minimize risk and build joint value.

Talent and partnership potential Given a small team (11-50 employees) and a stated transition from Nanna Therapeutics to a broader Astellas network, propose staff augmentation, outsourcing of niche assays, or co-development agreements to accelerate timelines and expand capabilities.